EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial

Sefri N Sofia, Udin Bahrudin, Ilham Uddin, Muhammad A Sobirin, Erna Setiawati, Galuh Hardaningsih, Kevin C Tjandra, Edward Ks Limijadi

Narra J · 2025

DOI: 10.52225/narra.v5i1.1301 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Narra J, 2025. Verfasst von Sefri N Sofia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia. Hauptthemen laut MEDLINE: Phosphodiesterase 3 Inhibitors, Cilostazol, Cardiorespiratory Fitness, Hypertension, Pulmonary. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many patients with acyanotic shunt congenital heart disease (CHD) are diagnosed only in adulthood, by which time pulmonary hypertension (PH) has developed, impairing their functional class and cardiorespiratory fitness. While PH treatments are limited and expensive, cilostazol, a phosphodiesterase-3 inhibitor, has shown potential in reducing pulmonary artery pressure and improving heart function, offering hope for better patient outcomes. The aim of this study was to evaluate the effects of cilostazol on cardiorespiratory fitness and functional class in patients with acyanotic shunt CHD with PH using a randomized, double-blind, placebo-controlled trial. The trial was conducted at Dr. Kariadi Hospital, Semarang, Indonesia, from March 2022 to March 2023. Patients aged 14–75 years were randomly assigned to receive cilostazol (initially 200 mg, later adjusted to 100 mg) or placebo for three months. Cardiorespiratory fitness was assessed using the six-minute walk test (6MWT) and VO2 max at pre-intervention and three months post-intervention. After three months, the mean 6MWT was not significantly different between cilostazol and placebo groups (319.65±50.52 vs 317.65±45.26 meters; p=0.090). Similarly, the VO2 max was also not significantly different between cilostazol and placebo groups (10.74±2.59 mL/kg/min vs 10.73±2.8 mL/kg; p=0.099). However, the percentage of patients who had functional class improvement was significantly higher in the cilostazol group compared to the placebo group (90% vs 30%; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 3 InhibitorsCilostazolCardiorespiratory FitnessHypertension, PulmonaryHeart Defects, CongenitalHumansDouble-Blind MethodMaleAdultFemaleMiddle AgedAdolescentIndonesiaAgedYoung AdultWalk Test

Stichwörter der Autor:innen

Congenital heart diseaseacyanoticcardiorespiratory fitnesscilostazolsix-minute walk test

Substanzen

Phosphodiesterase 3 InhibitorsCilostazol

Autor:innen und Institutionen

  • Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia.
  • Department of Cardiology and Vascular Medicine, Dr. Kariadi Hospital, Semarang, Indonesia.
  • Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia.
  • Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Dr. Kariadi Hospital, Semarang, Indonesia.
  • Department of Pediatrics, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia.
  • Department of Pediatrics, Faculty of Medicine, Dr. Kariadi Hospital, Semarang, Indonesia.

Zitieren

APA

Sofia, S. N., Bahrudin, U., Uddin, I., Sobirin, M. A., Setiawati, E., Hardaningsih, G., Tjandra, K. C., & Limijadi, E. K. (2025). Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial. Narra J. https://doi.org/10.52225/narra.v5i1.1301

Vancouver

Sofia SN, Bahrudin U, Uddin I, Sobirin MA, Setiawati E, Hardaningsih G, et al. Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial. Narra J. 2025. doi:10.52225/narra.v5i1.1301

BibTeX
@article{Sofia2025,
  author = {Sofia, Sefri N and Bahrudin, Udin and Uddin, Ilham and Sobirin, Muhammad A and Setiawati, Erna and Hardaningsih, Galuh and Tjandra, Kevin C and Limijadi, Edward Ks},
  title = {Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial},
  journal = {Narra J},
  year = {2025},
  doi = {10.52225/narra.v5i1.1301}
}
Kostenlos starten →